Ultragenyx Terminates UX701 Wilson Disease Study After Goals Not Met
Ultragenyx Pharmaceutical is terminating its UX701 study for Wilson disease because it did not achieve study goals.
Related stories
Sansiri Reports Quarterly Net Profit of 1,258 Million Baht
M impact | EQUITY | Nov 13, 2026, 01:56 AM UTC
CATL's Shares Rise 1.9% in Hong Kong
L impact | EQUITY | Nov 13, 2026, 01:53 AM UTC
Taiwan benchmark stock index rises as much as 3.2% to 44,489.48
M impact | EQUITY | Nov 13, 2026, 01:40 AM UTC
Mirendil Raises $1 Billion in Series A Funding
AI-tools startup Mirendil raised $1 billion in a Series A round led by Kleiner Perkins and Clearlake Capital.
M impact | EQUITY | Nov 13, 2026, 01:30 AM UTC
Asian session market picture: S&P 500 +0.35%, Nasdaq 100 +0.52%; USD/JPY +0.02%, WTI -0.41%, 9984 leads volume
Asian session market picture. US index futures: S and P futures is up 0.35 percent, Nasdaq futures is up 0.52 percent, Dow futures is up 0.21 percent and Russell futures is up 0.21
M impact | EQUITY | Nov 13, 2026, 01:30 AM UTC
AF Legal Group Posts Q1 Revenue of A$10.0 Million
M impact | EQUITY | Nov 13, 2026, 01:29 AM UTC